Shopping Cart
- Remove All
- Your shopping cart is currently empty
QTX125, a powerful and highly specific HDAC6 inhibitor, demonstrates exceptional selectivity in comparison to other HDACs, resulting in robust antitumor activity[1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | QTX125, a powerful and highly specific HDAC6 inhibitor, demonstrates exceptional selectivity in comparison to other HDACs, resulting in robust antitumor activity[1]. |
In vitro | QTX125 (25-500 nM; 24-48 hours) treatment induces apoptosis, evidenced by annexin V/propidium iodide double staining and cleavage of caspase-9, caspase-8, caspase-3, and PARP[1]. In MCL cell lines MINO, REC-1, IRM-2, and HBL-2, QTX125 (10 nM, 10 μM, 100 μM) induces dose-dependent hyperacetylation of α-tubulin[1]. QTX125 exhibits the strongest growth-inhibitory effects in Burkitt cell lymphoma, follicular lymphoma, and mantle cell lymphoma (MCL)[1]. |
In vivo | QTX125 (60 mg/kg; i.p.; daily for 5 days; for 4 weeks) treatment inhibits tumor growth in REC-1 or MINO xenografts in nude mice[1]. |
Molecular Weight | 417.41 |
Formula | C23H19N3O5 |
Cas No. | 1279698-31-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.